A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC - UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

被引：2
|
作者：
Jaenne, P. A. [1 ]
Ahn, M. -J. [2 ]
Kim, D. -W. [3 ]
Kim, S. -W. [4 ]
Planchard, D. [5 ]
Ramalingam, S. S. [6 ]
Frewer, P. [7 ]
Cantarini, M. [8 ]
Ghiorghiu, S. [9 ]
Yang, J. C. -H. [10 ]
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med,Hematol,Oncol, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] Gustave Roussy, Dept Med Oncol & Translat Res, Thorac Unit, Villejuif, France
[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[7] Astra Zeneca, ECD Biometr, Macclesfield, Cheshire, England
[8] Astra Zeneca, Global Med Dept, Oncol, Macclesfield, Cheshire, England
[9] Astra Zeneca, Global Med Dev, Luton, Herts, England
[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv128.5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of Osimertinib (AZD9291) in Chinese Patients with Advanced NSCLC: A Phase I Study
    Cao, Junning
    Chang, Jianhua
    Zhang, Clara
    Leaw, Shiang Jiin
    Wang, Jia
    Cantarini, Mireille
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1252 - S1253
  • [2] Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/II Study
    Cho, B. C.
    Han, J.
    Kim, S.
    Lee, K.
    Kim, D.
    Lee, Y.
    Lee, G.
    Lee, J.
    Cho, E. K.
    Kim, J.
    Lee, S. S.
    Min, Y. J.
    Kim, J.
    Shin, S. W.
    Kim, H. R.
    Hong, M. H.
    Ahn, J. S.
    Kang, S.
    Kim, S.
    Jang, S. B.
    Choi, S.
    Ahn, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S453 - S453
  • [3] Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
    Kenichi Koyama
    Satoru Miura
    Satoshi Watanabe
    Satoshi Shoji
    Jun Koshio
    Yoshiki Hayashi
    Daisuke Ishikawa
    Ko Sato
    Takao Miyabayashi
    Masaaki Okajima
    Takeshi Ota
    Tomohiro Tanaka
    Naoya Matsumoto
    Hideyuki Kuriyama
    Tetsuya Abe
    Koichiro Nozaki
    Kosuke Ichikawa
    Rie Kondo
    Hiroshi Tanaka
    Toshiaki Kikuchi
    Scientific Reports, 12
  • [4] Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
    Koyama, Kenichi
    Miura, Satoru
    Watanabe, Satoshi
    Shoji, Satoshi
    Koshio, Jun
    Hayashi, Yoshiki
    Ishikawa, Daisuke
    Sato, Ko
    Miyabayashi, Takao
    Okajima, Masaaki
    Ota, Takeshi
    Tanaka, Tomohiro
    Matsumoto, Naoya
    Kuriyama, Hideyuki
    Abe, Tetsuya
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Kondo, Rie
    Tanaka, Hiroshi
    Kikuchi, Toshiaki
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [5] EGFR resistant T790M mutation in NSCLC: real-life data of patients treated with AZD9291
    Hochmair, M.
    Holzer, S.
    Setinek, U.
    Filipits, M.
    Mohn-Staudner, A.
    Korger, M.
    Fabikan, H.
    Pirker, C.
    Burghuber, O. C.
    WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (19-20) : 831 - 831
  • [6] Long Progression Free Survival and Overall Survival in Advanced NSCLC Patients with EGFR Mutation and Complete Response with TKI Treatment
    Macedo-Perez, O.
    Lyra-Gonzalez, I.
    Marroquin-Flores, D.
    Cruz-Rico, G.
    Ramirez-Tirado, L.
    Valdez-Rojas, L.
    Tabares-Nanez, A.
    Gonzales-Nogales, J.
    Arrieta, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2087 - S2087
  • [7] YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.
    Cho, Byoung Chul
    Han, Ji-Youn
    Kim, Sang-We
    Lee, Ki Hyeong
    Kim, Dong-Wan
    Lee, Yun-Gyoo
    Lee, Gyeong-won
    Lee, Jong-Seok
    Cho, Eun Kyung
    Kim, Joo-Hang
    Lee, Sung Sook
    Min, Young Joo
    Kim, Jin-Soo
    Shin, Sang Won
    Kim, HyeRyun
    Hong, Min Hee
    Ahn, Jin Seok
    Choi, Soongyu
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M-Positive EGFR-Mutant NSCLC
    Planchard, David
    Kris, Mark
    Besse, Benjamin
    Hozak, Rebecca
    He, Shuang
    Gan, Frank
    Wolff, Katharina
    Chao, Bo
    Yu, Helena
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1071 - S1071
  • [9] AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
    Ahn, M. J.
    Tsai, C. M.
    Yang, J. C. H.
    Shepherd, F. A.
    Satouchi, M.
    Kim, D. W.
    Bazhenova, L.
    Hirashima, T.
    Rukazenkov, Y.
    Cantarini, M.
    Mann, H.
    Ramalingam, S. S.
    Mitsudomi, T.
    Jaenne, P. A.
    Goss, G. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S625 - S626
  • [10] Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.
    Ahn, Myung-Ju
    Han, Ji-Youn
    Kim, Sang-We
    Lee, Ki Hyeong
    Kim, Dong-Wan
    Lee, Yun-Gyoo
    Cho, Eun Kyung
    Lee, Gyeong-won
    Lee, Jong-Seok
    Kim, Joo-Hang
    Kim, Jin-Soo
    Min, Young Joo
    Lee, Sung Sook
    Shin, Sang Won
    Kim, HyeRyun
    Hong, Min Hee
    Ahn, Jin Seok
    Lee, Seoung Oh
    Kim, Sohee
    Cho, Byoung Chul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345